Share Twitter LinkedIn Facebook Email Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here:Â https://meetinglibrary.asco.org/record/185846/abstract
FDA Approves Deciphera Vimseltinib / Romvimza for symptomatic tenosynovial giant cell tumor (TGCT) patients Other 2 Mins Read
FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For? Other 3 Mins Read
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read